- Home
- WLKP vs AKBA Comparison
WLKP vs AKBA Comparison
Compare WLKP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- AKBA
- Stock Information
- Founded
- WLKP 2014
- AKBA 2007
- Country
- WLKP United States
- AKBA United States
- Employees
- WLKP N/A
- AKBA N/A
- Industry
- WLKP Major Chemicals
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- AKBA Health Care
- Exchange
- WLKP Nasdaq
- AKBA Nasdaq
- Market Cap
- WLKP 741.1M
- AKBA 861.7M
- IPO Year
- WLKP 2014
- AKBA 2014
- Fundamental
- Price
- WLKP $21.00
- AKBA $2.94
- Analyst Decision
- WLKP
- AKBA Strong Buy
- Analyst Count
- WLKP 0
- AKBA 5
- Target Price
- WLKP N/A
- AKBA $6.90
- AVG Volume (30 Days)
- WLKP 50.5K
- AKBA 2.9M
- Earning Date
- WLKP 11-04-2025
- AKBA 11-06-2025
- Dividend Yield
- WLKP 8.99%
- AKBA N/A
- EPS Growth
- WLKP N/A
- AKBA N/A
- EPS
- WLKP 1.49
- AKBA N/A
- Revenue
- WLKP $1,101,803,000.00
- AKBA $203,733,000.00
- Revenue This Year
- WLKP $3.27
- AKBA $43.91
- Revenue Next Year
- WLKP $13.98
- AKBA $32.09
- P/E Ratio
- WLKP $14.04
- AKBA N/A
- Revenue Growth
- WLKP N/A
- AKBA 16.75
- 52 Week Low
- WLKP $20.63
- AKBA $1.26
- 52 Week High
- WLKP $25.04
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- WLKP 41.69
- AKBA 51.11
- Support Level
- WLKP $20.80
- AKBA $2.66
- Resistance Level
- WLKP $21.45
- AKBA $3.01
- Average True Range (ATR)
- WLKP 0.37
- AKBA 0.12
- MACD
- WLKP 0.02
- AKBA 0.04
- Stochastic Oscillator
- WLKP 35.92
- AKBA 77.14
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.